XML 33 R9.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues for the three and nine months ended September 30, 2025 and 2024 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
ORLADEYO:
U.S.$141,557 $103,112 $402,054 $278,987 
Outside of U.S.17,520 13,207 48,103 34,487 
Total ORLADEYO159,077 116,319 450,157 313,474 
Other revenues318 766 18,125 5,704 
Total revenues$159,395 $117,085 $468,282 $319,178 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues, and royalties. Other revenues primarily relate to the Company’s product sales and royalties for peramivir.
No individual country outside of the U.S. exceeded 10% of total revenues for the three and nine months ended September 30, 2025 and 2024.